Zoar Ltd(ZOAR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 16.28 | EPS (ttm) | 0.21 | Insider Own | 7.36% | Shs Outstand | 8.5M | Perf Week | -34.24% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.14% | Shs Float | 7.9M | Perf Month | -11.05% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 3.58% | Short Float | 0.31% | Perf Quarter | -40.88% |
| Income | 0.00B | P/S | 756.12 | EPS this Y | - | Inst Trans | 0.29% | Short Ratio | 1.4 | Perf Half Y | -50.75% |
| Sales | 0.00B | P/B | 2.85 | EPS next 5Y | - | ROA | 9.32% | Short Interest | 0.02M | Perf YTD | -46.96% |
| Book/sh | 1.18 | P/C | 1512.24 | EPS past 3/5Y | 15.09% -48.52% | ROE | 371.29% | 52W High | -67.73% ($10.47) | Perf Year | -40.48% |
| Cash/sh | 0 | P/FCF | 252.04 | Sales past 3/5Y | - | ROIC | 15.95% | 52W Low | 39.09% ($2.43) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 100.44% | Gross Margin | -4026.32% | Volatility(W/M) | 14.08% 15.21% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 836.87 | Sales Y/Y TTM | 52% | Oper. Margin | -12623.68% | ATR (14) | 0.8 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.02 | EPS Q/Q | 95.04% | Profit Margin | 4247.37% | RSI (14) | 42.1 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.04 | Sales Q/Q | 16.67% | SMA20 | -20.09% ($4.23) | Beta | 1.38 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -29.24% ($4.78) | Rel Volume | 1.25 | Prev Close | $6.17 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -45.14% ($6.16) | Avg Volume(3M) | 0.02M | Price | $3.38 |
| IPO | 2024/9/16 | Option/Short | No/Yes | Trades | 331 | Volume | 21,986 | Change | -45.22% |
💊 A pharmaceutical company that develops and produces drug ingredients and intermediates to supply global pharmaceutical companies. Established in 2012, it handles ingredients for various therapeutic areas, including oncology, anticoagulation, antimalarial, antiviral, bronchodilation, and respiratory diseases, and also provides contract development and manufacturing services for complex ingredients. It has expanded its access to capital markets through listing on the U.S. stock exchange.
Over the past 1 year, on the lower side
68% below its 1-year high.
Traded about as much as usual. That is 125% of its average volume.
ZOAR has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $1,628. Peers typically go for $1,366.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 3.6%.
Tap to view numbers
It ranks #435 of 598 in the industry
Based on market cap of $30M.
FAQ
ZOAR belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of ZOAR is approximately $30M, ranking 4,979 within its sector.
ZOAR has a P/E ratio of approximately 16.3x, which can be used to assess its valuation relative to the Healthcare sector average.
ZOAR has recorded a 52-week high of $10.47 and a low of $2.43.